TRVN
TREVENA INC
stockOTC
trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1M | 0.01 | 2026-09-25 | -95.54% | 103.311 |
| 3M | 0.01 | 2026-07-20 | -95.50% | 63.139 |
| 6M | 0.01 | 2026-04-20 | -95.50% | -35.083 |
| 1Y | 0.02 | 2025-10-21 | -97.50% | -35.450 |
| 2Y | 1.92 | 2024-10-21 | -99.97% | — |
| 5Y | 693.75 | 2021-10-21 | -100.00% | -52.195 |
TREVENA INC (OTC:TRVN) stock price today is $0.00, and today's volume is 4,129. TRVN is down 99.242% today. The 30 day average volume is 775. TRVN market cap is $426 with 852,933 shares outstanding.